Skip to main content
Figure 4 | BMC Medical Genomics

Figure 4

From: Genomic signatures for predicting survival and adjuvant chemotherapy benefit in patients with non-small-cell lung cancer

Figure 4

Kaplan Meier analysis: 37-gene signature treatment response predictions for independent Validation Series B. Patients in (A) Predicted ‘ACT-responder’ group exhibit significantly improved rate of DSS when treated with ACT compared to OBS alone. Patients in (B) Predicted ‘ACT non-responder’ group do not exhibit a significant difference in DSS between either treatment arm of the trial. Multivariate Cox Proportional Hazard analysis included age, gender, stage, NSCLC histological subtype and treatment (ACT or OBS).

Back to article page